Bristol-Myers Squibb Company (BMY)

$48.61 +0.35 (0.73%)
Market Cap 98.39B
Revenue (ttm) 48.30B
Net Income (ttm) -8.95B
EPS (ttm) N/A
PE Ratio 7.16
Forward PE 7.39
Profit Margin -18.53%
Debt to Equity Ratio 2.81
Volume 3,576,129
Avg Vol 13,220,742
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 69%
Beta 0.36
Analysts Sell
Price Target $52.28

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 609 252 4621
Website: www.bms.com
Address:
Route 206 & Province Line Road, Princeton, United States
Cashflow62
Cashflow62 Aug. 21 at 5:01 PM
$BMY One of the final trades just now on CNBC. Finally.....
0 · Reply
3DBuilds
3DBuilds Aug. 21 at 3:33 PM
$BMY isnt it investing in CRISPR tech some gene editing company
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 21 at 3:32 PM
$RADX nice table of historical comps in radiopharm. we’re super early here! $NVS $BMY $LNTH $CATX
0 · Reply
chopnate
chopnate Aug. 21 at 12:26 PM
$BMY Bristol-Myers Squibb Company is a large pharmaceutical company. It faces a "patent cliff" as key drugs lose exclusivity. Its valuation depends on its ability to replenish its pipeline through R&D and M&A. A value play in pharma with a high yield.
1 · Reply
iQuicky
iQuicky Aug. 20 at 7:40 PM
$BMY looking good
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Aug. 20 at 5:27 PM
$SLS Not saying its 100% for sure, but its close, 99.99%, when a Big Pharma Sees the Gps Phase 3 Results and Knows Gps is Getting FDA Approval - to treat upwards of 25,000 AML Remission Patients each year - a $5B + TAM - just for the 10,000 patients getting into a Second Remission Each Year AML CR2, I think $ABBV $BMY and $MRK will all Want That MONEY. P3 Results will be announced ANY DAY NOW - and for sure won't be Much longer.
2 · Reply
MF__DOOM
MF__DOOM Aug. 20 at 4:54 PM
$XBI bouncing? $LLY $BMY $MRNA $JNJ
1 · Reply
SniperPro
SniperPro Aug. 20 at 2:22 PM
$LXRX BREAKING 🚨 Another Partnership news is imminent—why else would they be covering so aggressively? Use your head. Something big is coming, and they know it. 💥 $NVO $1B + Partner deal completed 💥 $VTRS Sota + Asian continent = $$$ 💥 LX9211 Partnership Deal Pending 💥 Inpefa USA/EU Partnership Deal Pending 💥 $BMY or $PFE next announcement ??? Oh yeah, I'm sure the massive covering is just a coincidence—definitely has nothing to do with SOTA gearing up to launch across the entire Asian market. Institutions always pile in at high volume for absolutely no reason, right? Totally normal behavior. But hey, keep pretending this is just noise while the smart money positions ahead of the news...
2 · Reply
ZacksResearch
ZacksResearch Aug. 20 at 2:12 PM
$BMY’s new schizophrenia drug Cobenfy: A significant addition or a gamble? 🤔 🚀 FDA approval broadens BMY’s portfolio 📈 Encouraging initial sales of $62M in H1 2025 ⚠️ Phase III ARISE study results fell short of expectations Is BMY’s pipeline strategy enough to offset generic competition? Full analysis here 👉 https://www.zacks.com/stock/news/2740252/does-cobenfy-have-the-potential-to-become-a-top-drug-for-bmy?cid=sm-stocktwits-2-2740252-body-8562&ADID=SYND_STOCKTWITS_TWEET_2_2740252_BODY_8562
0 · Reply
Cashflow62
Cashflow62 Aug. 20 at 1:59 PM
$BMY Solid......
0 · Reply
Latest News on BMY
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Aug 19, 2025, 1:32 PM EDT - 1 day ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

MDT XRAY

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Aug 18, 2025, 6:00 AM EDT - 3 days ago

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

Aug 15, 2025, 1:34 PM EDT - 5 days ago

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

AMCR ARE BXP CAG CPB CVX DOC

Dividend Harvesting Portfolio Week 232: $23,200 Allocated, $2,467.76 In Projected Dividends

Aug 14, 2025, 8:45 AM EDT - 7 days ago

Dividend Harvesting Portfolio Week 232: $23,200 Allocated, $2,467.76 In Projected Dividends

BP MO O SLB SPYI

3 SWANs On Sale

Aug 8, 2025, 7:00 AM EDT - 13 days ago

3 SWANs On Sale

ELV REXR

3 Dividend Stocks for August 2025

Aug 5, 2025, 11:01 AM EDT - 16 days ago

3 Dividend Stocks for August 2025

AMGN POR

Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity

Aug 4, 2025, 10:53 PM EDT - 16 days ago

Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity

Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Aug 4, 2025, 4:16 PM EDT - 16 days ago

Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Bristol-Myers Squibb: Buy The Weakness

Aug 4, 2025, 6:03 AM EDT - 17 days ago

Bristol-Myers Squibb: Buy The Weakness

Bristol-Myers Squibb: Declines Have Gone Too Far

Aug 2, 2025, 10:42 AM EDT - 19 days ago

Bristol-Myers Squibb: Declines Have Gone Too Far

Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields

Aug 1, 2025, 1:42 PM EDT - 19 days ago

Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields

Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline

Aug 1, 2025, 1:25 PM EDT - 19 days ago

Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline

Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)

Aug 1, 2025, 1:14 PM EDT - 19 days ago

Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Aug 1, 2025, 12:01 PM EDT - 20 days ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

ABBV AMGN AZN GILD GSK JNJ LLY

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 20 days ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat

Aug 1, 2025, 8:30 AM EDT - 20 days ago

Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 20 days ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:40 PM EDT - 20 days ago

Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

Jul 31, 2025, 3:35 PM EDT - 20 days ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AMGN AZN GILD GSK JNJ LLY

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

Jul 31, 2025, 3:00 PM EDT - 20 days ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AMGN AZN GILD GSK JNJ LLY

Trump pressures 17 pharma CEOs to cut US drug prices

Jul 31, 2025, 2:28 PM EDT - 20 days ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AMGN AZN GILD GSK JNJ LLY

Trump posts letters to 17 pharmaceutical companies about drug prices

Jul 31, 2025, 2:19 PM EDT - 20 days ago

Trump posts letters to 17 pharmaceutical companies about drug prices

ABBV GILD LLY PFE AMGN AZN GSK

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

Jul 31, 2025, 1:48 PM EDT - 20 days ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

ABBV AMGN AZN GILD GSK JNJ LLY

Bristol Myers posts better-than-expected second quarter results on strength of top sellers

Jul 31, 2025, 7:01 AM EDT - 21 days ago

Bristol Myers posts better-than-expected second quarter results on strength of top sellers

Bristol Myers Squibb Reports Second Quarter Financial Results for 2025

Jul 31, 2025, 6:59 AM EDT - 21 days ago

Bristol Myers Squibb Reports Second Quarter Financial Results for 2025

Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' July DiviDogs

Jul 30, 2025, 5:59 PM EDT - 21 days ago

Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' July DiviDogs

BBY CAG EQR FRT KIM KMI MO

How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?

Jul 30, 2025, 10:15 AM EDT - 22 days ago

How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?

Bristol Myers, Bain Capital form new company to develop immunology drugs

Jul 28, 2025, 5:59 PM EDT - 23 days ago

Bristol Myers, Bain Capital form new company to develop immunology drugs

Bristol Myers Squibb and Bain Capital Form New Immunology Company

Jul 28, 2025, 5:05 PM EDT - 23 days ago

Bristol Myers Squibb and Bain Capital Form New Immunology Company

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Jul 28, 2025, 4:16 PM EDT - 23 days ago

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector

Jul 28, 2025, 2:06 PM EDT - 23 days ago

Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector

ABBV CI CVS HUM MRK XBI XLV

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

Jul 25, 2025, 6:59 AM EDT - 27 days ago

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

Jul 21, 2025, 6:59 AM EDT - 4 weeks ago

Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

July's 5 Dividend Growth Stocks With Yields Up To 7.96%

Jul 18, 2025, 2:46 PM EDT - 4 weeks ago

July's 5 Dividend Growth Stocks With Yields Up To 7.96%

ABBV APAM BLK EBF MRK NWE PFE

Bristol Myers' drug fails to meet main goal of late-stage anemia trial

Jul 18, 2025, 7:16 AM EDT - 4 weeks ago

Bristol Myers' drug fails to meet main goal of late-stage anemia trial

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Jul 18, 2025, 6:59 AM EDT - 4 weeks ago

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

Jul 17, 2025, 11:47 AM EDT - 5 weeks ago

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

PFE

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients

Jul 17, 2025, 7:21 AM EDT - 5 weeks ago

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients

PFE

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

Jul 17, 2025, 6:59 AM EDT - 5 weeks ago

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price

Jul 17, 2025, 6:30 AM EDT - 5 weeks ago

Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price

PFE

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Jul 14, 2025, 1:52 PM EDT - 5 weeks ago

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

Jul 11, 2025, 5:23 PM EDT - 5 weeks ago

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

AES AMCR ARE CAG CPB CVX D

Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends

Jul 10, 2025, 8:45 AM EDT - 6 weeks ago

Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends

BP ENB MO SLG TFC

Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company

Jul 10, 2025, 3:01 AM EDT - 6 weeks ago

Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company

June Readers Tagged 13 Ideal Dividend Dogs From 16 "Safer" Out Of 38 ReFa/Ro

Jul 8, 2025, 12:36 PM EDT - 6 weeks ago

June Readers Tagged 13 Ideal Dividend Dogs From 16 "Safer" Out Of 38 ReFa/Ro

ABR AGNC CAG CPB DOW DX ECC

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

Jul 8, 2025, 10:41 AM EDT - 6 weeks ago

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

GILD JNJ NVO PFE VRTX

2 Wonderful Dividends At Bargain Basement Prices

Jul 7, 2025, 11:45 AM EDT - 6 weeks ago

2 Wonderful Dividends At Bargain Basement Prices

REXR

Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset

Jul 1, 2025, 6:25 AM EDT - 7 weeks ago

Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset

Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)

Jun 29, 2025, 9:00 AM EDT - 7 weeks ago

Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

Jun 26, 2025, 10:05 PM EDT - 7 weeks ago

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

Cashflow62
Cashflow62 Aug. 21 at 5:01 PM
$BMY One of the final trades just now on CNBC. Finally.....
0 · Reply
3DBuilds
3DBuilds Aug. 21 at 3:33 PM
$BMY isnt it investing in CRISPR tech some gene editing company
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 21 at 3:32 PM
$RADX nice table of historical comps in radiopharm. we’re super early here! $NVS $BMY $LNTH $CATX
0 · Reply
chopnate
chopnate Aug. 21 at 12:26 PM
$BMY Bristol-Myers Squibb Company is a large pharmaceutical company. It faces a "patent cliff" as key drugs lose exclusivity. Its valuation depends on its ability to replenish its pipeline through R&D and M&A. A value play in pharma with a high yield.
1 · Reply
iQuicky
iQuicky Aug. 20 at 7:40 PM
$BMY looking good
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Aug. 20 at 5:27 PM
$SLS Not saying its 100% for sure, but its close, 99.99%, when a Big Pharma Sees the Gps Phase 3 Results and Knows Gps is Getting FDA Approval - to treat upwards of 25,000 AML Remission Patients each year - a $5B + TAM - just for the 10,000 patients getting into a Second Remission Each Year AML CR2, I think $ABBV $BMY and $MRK will all Want That MONEY. P3 Results will be announced ANY DAY NOW - and for sure won't be Much longer.
2 · Reply
MF__DOOM
MF__DOOM Aug. 20 at 4:54 PM
$XBI bouncing? $LLY $BMY $MRNA $JNJ
1 · Reply
SniperPro
SniperPro Aug. 20 at 2:22 PM
$LXRX BREAKING 🚨 Another Partnership news is imminent—why else would they be covering so aggressively? Use your head. Something big is coming, and they know it. 💥 $NVO $1B + Partner deal completed 💥 $VTRS Sota + Asian continent = $$$ 💥 LX9211 Partnership Deal Pending 💥 Inpefa USA/EU Partnership Deal Pending 💥 $BMY or $PFE next announcement ??? Oh yeah, I'm sure the massive covering is just a coincidence—definitely has nothing to do with SOTA gearing up to launch across the entire Asian market. Institutions always pile in at high volume for absolutely no reason, right? Totally normal behavior. But hey, keep pretending this is just noise while the smart money positions ahead of the news...
2 · Reply
ZacksResearch
ZacksResearch Aug. 20 at 2:12 PM
$BMY’s new schizophrenia drug Cobenfy: A significant addition or a gamble? 🤔 🚀 FDA approval broadens BMY’s portfolio 📈 Encouraging initial sales of $62M in H1 2025 ⚠️ Phase III ARISE study results fell short of expectations Is BMY’s pipeline strategy enough to offset generic competition? Full analysis here 👉 https://www.zacks.com/stock/news/2740252/does-cobenfy-have-the-potential-to-become-a-top-drug-for-bmy?cid=sm-stocktwits-2-2740252-body-8562&ADID=SYND_STOCKTWITS_TWEET_2_2740252_BODY_8562
0 · Reply
Cashflow62
Cashflow62 Aug. 20 at 1:59 PM
$BMY Solid......
0 · Reply
ZacksResearch
ZacksResearch Aug. 20 at 1:12 PM
$BMY’s Cobenfy — the next blockbuster drug? The first new schizophrenia treatment in decades is already showing early sales momentum, with pipeline expansion potential adding more fuel to the story. Full breakdown here 👉 https://www.zacks.com/stock/news/2740252/does-cobenfy-have-the-potential-to-become-a-top-drug-for-bmy?cid=sm-stocktwits-2-2740252-teaser-8561&ADID=SYND_STOCKTWITS_TWEET_2_2740252_TEASER_8561
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 20 at 11:39 AM
$BMY https://finance.yahoo.com/m/1306786f-f828-35c9-9e23-8128eb872a46/fda-awards-breakthrough.html
0 · Reply
Cashflow62
Cashflow62 Aug. 19 at 4:41 PM
$BMY Perfect stock perfect storm. Totally under rated, low PE dividend over 5%. Don't over look this one.
0 · Reply
RRCORNER
RRCORNER Aug. 19 at 2:10 PM
$PPCB Don't be fooled by the lull. Propanc's EMT modulator stops metastasis and is a groundbreaking discovery for treating cancer. PPCB has over 90 patents. And there is a very large short position from yesterdays 67 million share day that could send the price flying like $RGC. $BMY $MRK need this for their Keytruda and Opdivo sales.
0 · Reply
Quantumup
Quantumup Aug. 19 at 12:08 PM
Piper Sandler🏁 $DAWN Overweight-$25 and said, Investor sentiment has declined following the first two 2025 earnings reports given concern around the potential plateauing of Ojemda ~1 year into launch. $RHHBY $NVS $PFE $BMY ALPMY Piper Sandler additionally said in its $DAWN initiation: We think the stock move is overdone and that these early decelerations are simply artifacts of a unique cancer indication wherein the prescribing physicians are risk-averse and slow to adopt novel therapies. And while the growth may be more gradual that the Street originally expected, we continue to believe the clinical data will support strong penetration longer term.
1 · Reply
Quantumup
Quantumup Aug. 19 at 10:32 AM
Piper Sandler🏁 $URGN Overweight/$36. $MRK $AZN $JNJ $BMY TEVA Piper Sandler said in its note: $URGN shares have been volatile in 2025 (e.g. ODAC briefing documents, ODAC panel vote, and ultimate FDA approval) but investors are starting to gain more confidence in the Zusduri launch. That said, we think the Street still underestimates peak sales potential in LG-IR-NMIBC and overestimates IP risk to the -102/-103 franchise. We think early commercial launch datapoints combined with updates from the Ph. III UTOPIA of UGN-103 will drive meaningful upside to $URGN shares over the next 12-18 months.
0 · Reply
nostic
nostic Aug. 18 at 4:24 PM
$BMY anybody know WHEN they put in the BTD application for Izalontamab?
0 · Reply
wwmeinc
wwmeinc Aug. 18 at 2:29 PM
$RNA ....Next Monday August 25/25...UK bank holiday...just saying/noting...Would be 'helpful' if $NVS just fulfils their part of the FT.com rumour/story/report this week and seal the $RNA buy out deal...change of control most likely in place for all Avidity Exec's....so they will be well taken care of...and with that out of the way...and after NVS mgmt Inv. bankers dropped the hammer on having anymore 'leaks' to the media...nothing really in the way now for closing this buy-out...oh....I believe we are all expecting something around ~$9B or so...always the possibility of another bidder as well...say... $BMY . All eyes/investment dollars and patient's hope's/dreams will be here though for DMD...safe and efficacy will be their headline. Patiently waiting...with all the risk/rewards that are known ;). Good trading and glta. https://optioncharts.io/options/RNA
0 · Reply
OnTheBalance
OnTheBalance Aug. 17 at 5:11 AM
$BMY market cap at $98.6B, 5 year stock performance at -22.11% Two acquisitions that could help reverse its fortunes, and unleash shareholders' gains for years to come. $SLS $PRME
2 · Reply
3DBuilds
3DBuilds Aug. 16 at 4:09 PM
$LLYX.X $BMY $JNJ
0 · Reply
RRCORNER
RRCORNER Aug. 16 at 3:24 PM
$PPCB Here is why $PPCB is up AH. EMT modulator could be a groundbreaking approach in cancer treatment. EMT is a biological process that enables tumors to spread to distant organs. EMT has been strongly linked to resistance against chemotherapy, immunotherapy, and targeted therapies. Propanc’s PRP EMT modulator has demonstrated remarkably strong results in NIH sponsored clinical trial. PPCB just uplisted to NASDAQ and has secured the first round of funding for trials. There are always risks of failure, but the potential for one of the biggest breakthroughs in cancer treatment looks real. $PFE $LLY $BMY $MRK https://richardacavalli.wixsite.com/greenplanetmicrocaps/ai-meets-energy
0 · Reply
RRCORNER
RRCORNER Aug. 15 at 9:34 PM
$PPCB EMT Modulator PRP slows metastasis dramatically. Very high value to $BMY $MRK and chemo and immunotherapy companies. Will likely fill big gap from $10.40 yesterday. Very low price, tiny market cap and extremely small float . . . could surprise soon. https://richardacavalli.wixsite.com/greenplanetmicrocaps/ai-meets-energy
0 · Reply